Quantcast
Last updated on April 16, 2014 at 7:44 EDT

Latest gene delivery Stories

2013-06-17 08:27:34

MOUNTAIN VIEW, Calif., June 17, 2013 /PRNewswire/ -- In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin® reagent for direct supply to biomedical researchers. RetroNectin® reagent is designed to enable efficient retroviral transduction of genes into hematopoietic stem cells as well as lymphocytes and other blood cells. The...

2013-06-17 08:27:22

DUBLIN, June 17, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/dfcq6z/gene_therapy) has announced a new report "Gene Therapy - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/dfcq6z/gene_therapy ] to its offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for...

2013-06-13 10:02:38

Engineered virus will improve gene therapy for blinding eye diseases Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration. Unlike current treatments, the new procedure — which...

2013-06-06 23:32:28

Glowing Plant´s Kickstarter crowdfunding campaign to end on June 7 at 1am EST. San Francisco, CA (PRWEB) June 05, 2013 Glowing Plant is taking the first step towards creating sustainable natural lighting for the planet by using synthetic biology and Genome Compiler´s software to create plants that glow in the dark. That´s right, the team at Glowing Plant is looking to create light without using any electricity, and has looked to crowdfund the entire project on Kickstarter....

2013-05-21 08:29:26

AMSTERDAM, The Netherlands, May 21, 2013 /PRNewswire/ -- uniQure B.V., a leader in the field of human gene therapy, today announced that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for Huntington's disease. The consortium is a pan-European collaboration consisting of uniQure as the coordinator, Lausanne University Hospital, Switzerland, University Medical Center Gottingen, Germany, and Maria...

2013-05-20 23:15:02

Selexis´ co-founder and scientific advisory board member will present, “Engineering the CHO Genome for Improved Transgene Integration and Expression” Geneva, Switzerland (PRWEB) May 20, 2013 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that the Company´s co-founder will present data on the Company´s core technology at...

2013-05-20 08:26:09

Production of Therapeutically Relevant Levels of Clotting Factor VIII Further Demonstrates Breadth and Leverage of this Novel Approach to Monogenic Diseases RICHMOND, Calif., May 20, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the successful application of Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has...

2013-05-09 04:21:22

OXFORD, England, May 9, 2013 /PRNewswire/ -- -- UshStat(R)video selected to showcase theme of "Life-changing Research" -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Seattle, Washington (USA) on 5-9 May 2013. The ARVO annual meeting is the largest gathering of eye and...

2013-04-12 08:25:18

Patent-pending PRCN-829 delivers multiple genes, including Factor H, neural growth factors and regulators of TDP-43 to treat neurodegenerative disease ALS BOGOTA, Colombia, April 12, 2013 /PRNewswire/ -- Startup biotechnology company Neuralgene (http://neuralgene.com) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy...

2013-04-08 23:01:38

ACGT today announced that seed money provided for innovative T-Cell immunotherapy cell and gene therapy research has led to two successful Clinical Trials for treatment of Acute Lymphoblastic Leukemia resulting in remissions in both children and adults who had no other hope of recovery. Stamford, Connecticut (PRWEB) April 08, 2013 Alliance for Cancer Gene Therapy, Inc. (ACGT), http://www.acgtfoundation.org, https://twitter.com/acgtfoundation, and https://www.facebook.com/acgtfoundation,...